Novartis launches study using smartphone app on MS

Novartis, producers of innovative healthcare solutions, has announced the launch of its elevateMS study. The study aims to utilize a mobile application for people with multiple sclerosis (MS) to collect sensor-based data to improve research.

The study incorporates a mobile app that allows participants to complete questionnaires, capture passive and active movement data, and complete functional tasks. Data are stored on the app where participants are able to view changes over time and inform researchers about living with MS.

"As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe," said Stanley Cohan, MD, PhD, medical director of Providence Multiple Sclerosis Center in Portland, Oregon. "With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.